tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
94.060USD
0.000
Fechamento 11/03, 16:00ETCotações atrasadas em 15 min
2.04BValor de mercado
PerdaP/L TTM

ANI Pharmaceuticals Inc

94.060
0.000

Mais detalhes de ANI Pharmaceuticals Inc Empresa

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.

Informações de ANI Pharmaceuticals Inc

Código da empresaANIP
Nome da EmpresaANI Pharmaceuticals Inc
Data de listagemMay 04, 2000
CEOMr. Nikhil Suresh Lalwani
Número de funcionários897
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
Endereço210 Main Street West
CidadeBAUDETTE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal56623
Telefone12186343500
Sitehttps://www.anipharmaceuticals.com/
Código da empresaANIP
Data de listagemMay 04, 2000
CEOMr. Nikhil Suresh Lalwani

Executivos da empresa ANI Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
26.96K
+19.17%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
70.05K
-11.39%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%

Detalhamento da receita

FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%

Distribuição de ações

Atualizado em: dom, 17 de ago
Atualizado em: dom, 17 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.64%
The Vanguard Group, Inc.
5.71%
Meridian Venture Partners
4.55%
Millennium Management LLC
4.50%
Global Alpha Capital Management Ltd.
3.87%
Outro
70.72%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.64%
The Vanguard Group, Inc.
5.71%
Meridian Venture Partners
4.55%
Millennium Management LLC
4.50%
Global Alpha Capital Management Ltd.
3.87%
Outro
70.72%
Tipos de investidores
Investidores
Proporção
Investment Advisor
44.67%
Investment Advisor/Hedge Fund
21.80%
Hedge Fund
17.80%
Individual Investor
7.52%
Private Equity
4.55%
Research Firm
3.65%
Corporation
2.86%
Bank and Trust
1.67%
Pension Fund
1.63%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
501
21.40M
95.98%
-2.10M
2025Q2
505
24.45M
112.92%
-1.14M
2025Q1
511
24.19M
111.77%
-1.42M
2024Q4
489
23.75M
109.53%
-1.38M
2024Q3
473
23.30M
110.79%
+2.44M
2024Q2
446
19.77M
94.29%
-402.06K
2024Q1
424
18.72M
89.20%
-877.00K
2023Q4
409
18.10M
88.69%
-881.29K
2023Q3
396
18.38M
91.57%
-127.77K
2023Q2
370
17.73M
90.91%
+852.82K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
Millennium Management LLC
1.00M
4.5%
-112.78K
-10.10%
Jun 30, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Deep Track Capital LP
700.00K
3.14%
--
--
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Invesco Pharmaceuticals ETF
2.7%
SPDR S&P Pharmaceuticals ETF
2.26%
Pacer US Small Cap Cash Cows Growth Leaders ETF
2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.69%
Innovator IBD 50 Fund ETF
1.3%
Invesco Dorsey Wright Healthcare Momentum ETF
1.07%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.04%
Invesco S&P SmallCap Health Care ETF
1.01%
Innovator IBD Breakout Opportunities ETF
0.9%
First Trust Small Cap Growth AlphaDEX Fund
0.7%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção2.7%
SPDR S&P Pharmaceuticals ETF
Proporção2.26%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.69%
Innovator IBD 50 Fund ETF
Proporção1.3%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.07%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporção1.04%
Invesco S&P SmallCap Health Care ETF
Proporção1.01%
Innovator IBD Breakout Opportunities ETF
Proporção0.9%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.7%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI